R APID EYE MOVEMENT sleep behavior disorder (RBD) is characterized by a loss of normal muscle atonia during rapid eye movement (REM) sleep resulting in undesirable and often violent motor activity associated with dream content. 1 Patients with idiopathic RBD (iRBD) can develop synucleinopathies associated with substantia nigra dysfunction, such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), or multiple system atrophy (MSA). 2 Among these conditions, PD was the main converted direction. 3, 4 The estimated risk of developing a neurodegenerative syndrome in iRBD patients was 17.7-33.1% at 5 years, 40.9-75.7% at 10 years, and 90.9% at 14 years. 5, 6 In addition, a pathology study showed that 94% of RBD patients with neurodegenerative disorders were patients with synucleinopathies. 7 Thus, iRBD likely represents the prodromal stage of synucleinopathy. Although iRBD patients develop MSA less frequently than patients with PD or DLB, RBD has been reported to occur in 88-100% of MSA patients. 8, 9 However, few studies have examined the relation between RBD and MSA.
Midbrain substantia nigra (SN) hyperechogenicity on transcranial sonography (TCS) is a potential early marker of PD. 10 TCS has been widely used to detect presymptomatic changes in PD. Here, we investigated the preclinical abnormalities revealed by TCS in patients with iRBD and MSA compared with those in patients with PD and normal controls. In addition, we examined the mechanisms of the relation between RBD and MSA.
METHODS Subjects
Twenty-two patients with iRBD, 21 patients with MSA, 22 patients with PD, and 21 healthy controls were recruited from a sleep disorder clinic and the inpatient ward of our department between 2011 and 2015. A standardized history was taken for each participant, with a focus on sleep, and all participants underwent a routine assessment that included a physical and neurological examination, necessary laboratory tests, and computed tomography or magnetic resonance imaging. The body mass index (BMI) was calculated for each participant based on his or her weight and height records (weight/ height 2 ). Based on polysomnographic recordings and clinical history, the iRBD patients (18 men and four women) fulfilled the diagnostic criteria of the revised version of the International Classification of Sleep Disorders. 11 None of the iRBD patients had neurodegenerative disease, especially PD or dementia. The probable MSA patients (15 men and six women) were confirmed according to the second consensus of MSA, including 16 MSA with cerebellar ataxia and five MSA with parkinsonism. 12 The PD patients (16 men and six women) were diagnosed according to the United Kingdom Parkinson's Disease Society Brain Bank criteria. 13 The diagnosis was confirmed by at least two experienced neurologists. The healthy controls (nine men and 12 women) had no severe medical illnesses, neurological disorders, or psychiatric diseases. Patients with a history of psychiatric drugs or calcifications on computed tomography were also excluded.
The participants and their families were given an explanation about the objectives of this study, and written informed consent was obtained. The study was approved by the ethics committee of the China-Japan Friendship Hospital.
Polysomnography
All participants underwent one night of videopolysomnography (PSG) monitoring recorded by a 32-montage electroencephalograph (9200K, Nihon Kohden, Japan). PSG included electroencephalography with 16 montages (FP1, FP2, F3, F4, C3, C4,  P3, P4, O1, O2, F7, F8, T3, T4, T5, and T6) to rule out epilepsy, as well as electrooculography, electromyography (EMG) on the chin and limbs, electrocardiography, nasal airflow, thoracic and abdominal respiratory movement, blood oxygen saturation, and snoring. The sleep architecture and other parameters were analyzed using POLYSMITH software and by visual analysis. Sleep stages were scored according to the criteria of the American Academy of Sleep Medicine Guidelines, 14 with modifications to allow the persistence of EMG tone during epochs that were clearly REM sleep. The presence of REM sleep without atonia was evaluated using submental and limb EMG activity recordings, whereas vocalizations and motor events were confirmed by video and microphone recordings.
TCS
TCS was performed following a standardized procedure. [15] [16] [17] A color-coded phased array ultrasound system (LOGIQ9, Milwaukee, WI, USA) equipped with a 1-3-MHz 3S probe was used in this study. The probe was used to detect signals through the right and left temporal bone windows in the axial plane, with a penetration depth of 14-16 cm and a dynamic range of 57-60 dB. Patients without a sufficient bone window for TCS were excluded.
The patient was posed in a supine position. One experienced sonographer examined the midbrain, third ventricle, and basal ganglia (BG) to ascertain the echogenicity of the substantia nigra (SN) and BG, as well as the width of the third ventricle. The image brightness and time gain were adapted as needed for the best visualization. The midbrain was identified by the characteristic butterfly-shaped structure surrounded by highly echogenic basal cisterns, and the brainstem raphe was detected as a continuous line with a high echogenicity at its center. The probe was tilted 10 upward to measure the largest transverse diameters of the third ventricle, which was surrounded by a thin hyperechogenic margin and had a low hyperechogenic signal. The third ventricle was measured from the ipsilateral to the contralateral inner layers of the hyperechogenic ependyma. The echogenicity of the BG, mainly the lenticular nucleus, was also semiquantitatively rated at this level. TCS images of a normal control are shown in Figure 1a -c. The images of the hyperechogenic signals in the SN, BG, and third ventricle obtained bilaterally from the temporal windows were stored digitally. The echo signals of the SN were classified according to the signal brightness into five grades using semi-quantitative visual scoring grades of I-V. If the signal brightness was graded as III or above, then the area of the SN hyperechogenicity was measured. SN echogenic sizes of >0.20 cm 2 were classified as normal, whereas sizes of 0.20 cm 2 and above were classified as abnormal, based on the previous references and the practices of our laboratory. The sensitivity was 86.4% for discriminating PD from normal controls, and the specificity was 95.2%. The positive predictive value (PPV) was 95.0% using the cut-off in our laboratory. The lenticular nucleus is isoechogenic to the surrounding brain parenchyma. A moderately or pronounced hyperechogenicity of the structures compared with the surrounding white matter was classified as abnormal. TCS images of a 64-year-old male patient with iRBD are shown in Figure 1d -f. All TCS examinations were performed by a single experienced neurosonologist who was blinded to the diagnosis.
Statistical analysis
Statistical analyses were performed using SPSS 17.0 (SPSS, Chicago, IL, USA). The data are expressed as the mean AE SD unless otherwise specified. One-way analysis of variance was used to analyze the quantitative variables for the four groups, including age, duration of RBD, width of the third ventricle, BMI, and sleep parameters. Comparisons of the prevalence of hyperechogenic signals in the SN or BG were performed using a χ 2 -test to assess the differences in the qualitative variables between groups. The sex ratio and the percentage of abnormal behaviors recorded by video or microphone were also analyzed. Spearman's correlation coefficient (r) was used to evaluate whether the duration of RBD, MSA, or PD was correlated with age, width of the third ventricle, BMI, or several sleep parameters. If hyperechogenic signals were observed in the SN or BG, then this signal was analyzed with age, duration, and sleep parameters using a binary logistic regression. The significance level was set at P < 0.05.
RESULTS
The demographic and clinical data for patients with iRBD, MSA, PD, and normal controls are summarized in Table 1 . The patients with MSA were younger than patients with iRBD or PD (P = 0.003). The control group had more women than the iRBD, MSA, and PD groups (P = 0.041). There was no difference in the duration of RBD among iRBD, MSA, and PD patients. The durations of MSA (3.81 AE 5.67 years) and PD (3.68 AE 2.53 years) were also similar. RBD preceded the onset of MSA in 76.2% of MSA patients, although all patients with MSA had RBD. Meanwhile, 68.2% of PD patients had RBD, and RBD preceded the onset of PD in 73.3% of PD patients. There was no difference in the duration of RBD before onset of PD (3.88 AE 7.83 years) or MSA (4.78 AE 8.94 years). The mean weight of PD patients was lower than that of the other three groups (P = 0.031), whereas the four groups had similar heights and BMI.
The patients with PD (86.4%) had higher percentages of unilateral or bilateral SN hyperechogenicity compared with patients with iRBD (31.8%), patients with MSA (23.8%), and normal controls (4.8%) (P < 0.001). Patients with iRBD or MSA also had more SN hyperechogenicity compared with normal controls. Fourteen MSA (66.7%) and 11 iRBD patients (50.0%) had hyperechogenicity unilaterally or bilaterally in the BG, and both of these groups had more hyperechogenicity than PD patients (18.2%) and normal controls (9.5%) (P < 0.001). SN hyperechogenicity without changes in the BG was found in 68.2% of patients with PD and 18.2% of patients with iRBD compared with 4.8% of patients with MSA and normal controls (P < 0.001). BG hyperechogenicity without SN changes was present in 47.6% of patients with MSA and 36.4% of patients with iRBD but was less common in patients with PD (0.0%) and normal controls (9.5%) (P = 0.001). Abnormalities in both the SN and BG were present in 13.6% of patients with iRBD, 19.0% of patients with MSA, and 18.2% of patients with PD. The width of the third ventricle increased in both iRBD and PD patients (P = 0.015) ( Table 1) .
Patients with MSA or PD had shorter total sleep time (P = 0.005), worse sleep efficiency (P = 0.010), and greater hypopnea index (P = 0.049). Longer durations and higher percentages for stage I sleep were observed in PD patients (P = 0.003, 0.001). The sleep parameters for patients with iRBD were similar to those of controls ( Table 2 ). The video and microphone recordings of iRBD patients (59.1%) showed obvious vocalizations and motor events. Abnormal behaviors were demonstrated by 33.3% of MSA patients and 31.8% of PD patients, while a history of dream-enacting behaviors and loss of REM atonia were found in all MSA patients and 63.6% of PD patients.
Age was positively correlated with the width of the third ventricle (r = 0.797, P < 0.001) in normal controls. In the MSA patient group, age and width of the third ventricle were positively correlated (r = 0.605, P = 0.013). In the PD patient group, age was correlated with width of the third ventricle 
DISCUSSION
TCS is an inexpensive, radiation-free, and widely available technique that can be used to visualize the cerebral parenchyma and ventricular system and may be used to identify a potential SN marker of prodromal PD. 16 The present study attempted to identify relations between iRBD and MSA using TCS. Hyperechogenicity in not only the SN but also the BG was explored. A greater proportion of PD patients demonstrated SN hyperechogenicity, whereas MSA patients showed higher percentages of BG hyperechogenicity. The percentage of abnormal hyperechogenicity in the iRBD group was between those in the PD and MSA groups.
The frequency of SN hyperechogenicity in iRBD and MSA patients was 31.8% and 23.8%, respectively, and thus was more frequent compared to control subjects (4.8%) and less frequent than in PD patients (86.4%). Approximately 80-90% of PD patients had abnormal hyperechogenicity of the SN. 18 The potential for TCS to predict PD was recently confirmed in a population-based study in which abnormal TCS at baseline was associated with an odds ratio of 16.7 for PD. 19 In MSA, the level of abnormal hyperechogenicity has varied with different reports, ranging from 6.25% to 50%. 18, [20] [21] [22] [23] As for iRBD, Unger et al. reported abnormal SN signals in five patients using TCS. 24 The first TCS casecontrol study showed a 37.3% midbrain hyperechogenicity in iRBD patients, which was significantly more frequent compared to control subjects (10.7%). 25 SN hyperechogenicity was subsequently identified in 36-54% of patients, as iRBD was considered to be prodromal for synucleinopathy. [26] [27] [28] [29] [30] Our results are similar to previous results, although there was no difference between iRBD and MSA on SN abnormalities.
In a prospective follow-up study, 62.5% of iRBD patients who developed synucleinopathy at baseline had TCS abnormalities, suggesting that TCS can detect subclinical changes and might reveal useful markers for identifying individuals at increased risk for development of synucleinopathies. 26 However, a subsequent study that included a 5-year follow-up showed that the SN alone was not a useful tool for identifying iRBD subjects who were at risk for developing PD or a synucleinopathy. 31 Previous studies focused on the relation between iRBD and PD and investigated only SN hyperechogenicity.
To investigate the relation between MSA and iRBD, the BG was also examined. Hyperechogenicity was present in the BG in 66.7% of MSA patients and 77%) atypical parkinsonism patients that were mainly MSA cases, but it was found in only five of 22 (23%) PD patients. 20 Further study confirmed that LN hyperechogenicity was found in 19% of PD patients aged younger than 60 years, 30% of PD patients aged 60 or older, and 75% of patients with MSA-P. 22 A normal echogenic SN combined with a hyperechogenic LN discriminated MSA from PD with a PPV of 100% (sensitivity, 65%; specificity, 100%). Behnke et al. yielded similar results in which a hyperechogenic LN as an indicator for atypical parkinsonism showed PPV and negative predictive values of 0.78 and 0.84, respectively. 21 When combined with other variables, the PPV in identifying PD and atypical parkinsonism increased significantly. Another prospective study showed that the classification accuracy of SN echogenicity at baseline was 93.9%, whereas the classification accuracy of BG hyperechogenicity for atypical parkinsonism was 68.2%. The low accuracy may have contributed to atypical parkinsonism enrolled as different types of parkinsonism. 18 A systematic review concluded that hyperecho-intensity of the LN was found often in atypical parkinsonism (79%) but considerably less often in patients with PD (23%) and healthy controls (6%). TCS of the LN alone was only moderately accurate when used to delineate atypical parkinsonism from PD. However, when combining other brain structures, the diagnostic accuracy could be improved considerably. 32 A normal SN echointensity and an increased intensity of the LN may indicate MSA. TCS showed a comparable accuracy with [ 18 F] fluorodeoxyglucose positron emission tomography for the differential diagnosis of neurodegenerative parkinsonism using this standard. 33 As for DLB, the patients had symmetrical SN hyperechogenicity, BG hyperechogenicity, and wider third ventricles. 34 The present study confirmed a greater BG hyperechogenicity in MSA patients compared with controls and PD patients. MSA and iRBD patients had higher percentages of BG hyperechogenicity and normal SN echo-intensity than controls and PD patients, and PD patients showed a greater SN hyperechogenicity with normal BG regions. iRBD patients had high echo-intensity of the BG, which likely indicates a possible preclinical stage of MSA.
In the prospective study by Iranzo et al., eight iRBD patients (30%) developed a neurodegenerative disorder after a follow-up of 2.5 years. Most PD (3/5) converters and all DLB (2/2) converters had SN hyperechogenicity, whereas only one MSA converter had a normal SN. 26 Although the BG was not investigated, we are uncertain about the effect of BG abnormalities on MSA. MSA had more widespread pathological changes and more rapid progression than PD. Increased accumulation of intracellular ferritin and reduced export of iron from the basis pontis, and to a lesser extent, the putamen, can lead to oxidative stress and mitochondrial dysfunction, which was reflected by BG hyperechogenicity. 35 iRBD patients had BG hyperechogenicity, which represented the early changes of basal ganglia and the risk of developing MSA. Clinical presentations of MSA occurred when pathology involved more systems. This might explain the low incidence of developing MSA in iRBD.
iRBD patients had almost normal sleep, whilst poor sleep efficiency, abnormal sleep architectures, more PLM, or hypopnea were found in patients with MSA or PD. The widespread neurodegenerative process disrupted sleep in the patients with PD or MSA. The abnormal hypopnea of MSA might contribute to a more widespread and severe dysfunction of brainstem structures. 36 Although a history of dreamenacting behaviors and loss of REM atonia were reported in patients with MSA and PD, vocalizations and motor events were more frequently recorded in patients with iRBD than in patients with MSA or PD. The degenerative course in the brainstem may explain the phenomenon. 8 Aging had an effect on width of the third ventricle in normal controls, MSA patients, and PD patients. In addition, PD and iRBD patients were older than the other participants, which may explain the differences in the width of the third ventricle.
There were some limitations in our study. First, the findings should be interpreted with caution because of the small sample size. Second, there was an obvious male predominance in the iRBD, MSA, and PD groups, whereas the control group had a similar number of men and women, which may have affected the results of our study. Third, Asian populations compared with Western populations have higher rates of a poor echo window on TCS, especially in women. 37 Some patients had to be excluded from the present study because of a poor echo window. Finally, PSG was recorded over one night, which may have affected the sleep parameters because of a first-night effect.
In summary, some iRBD patients had SN hyperechogenicity that could convert to PD, whereas others had BG hyperechogenicity that was similar to that for MSA and may represent another possible convert direction. Further prospective studies are required to determine whether BG hyperechogenicity in iRBD can serve as a predictor for such conversions. The present study further confirmed iRBD in the prodromal stage of synucleinopathy. TCS could detect subclinical changes and might provide useful markers for identifying individuals who are at increased risk for developing synucleinopathies.
